{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T16:52:34Z","timestamp":1649004754976},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"s31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p id=\"P1_w2aab3b7b9b1b6b1aab1c16b1Aa\">Vaccination is a safe and effective tool in the prevention of serious and deadly infectious diseases. The vaccinations delivered at routine adolescent visits are an integral part of preventing infection, as well as reducing school absenteeism as a result of illness. Current recommendations by the Advisory Committee on Immunization Practices include vaccinating during a single visit at age 11 or 12 years against pathogens including <jats:italic>Neisseria meningitidis<\/jats:italic>, which has been shown to cause invasive meningococcal infections; <jats:italic>Bordetella pertussis<\/jats:italic>, which has been shown to cause pertussis (whooping cough); and human papillomavirus, which has been shown to cause cervical cancer and genital warts. Additionally, annual influenza vaccination is recommended for adolescents without contraindications to the vaccine. In the present article, the authors summarize current recommendations for adolescent vaccines and their formulations, the infections that they prevent, contraindications to administration, vaccination rates, and the most commonly reported adverse events.<\/jats:p>","DOI":"10.7556\/jaoa.2014.043","type":"journal-article","created":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T21:55:17Z","timestamp":1393019717000},"page":"6-12","source":"Crossref","is-referenced-by-count":2,"title":["Recommended Vaccines for Adolescent Patients"],"prefix":"10.1515","volume":"114","author":[{"given":"Gregory H.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"2021042020250770289_j_jaoa.2014.043_ref_001_w2aab3b7b9b1b6b1ab2b1b1Aa","unstructured":"ACIP Childhood\/Adolescent Immunization Work GroupAkinsanya-BeysolowIJenkinsRMeissnerHCCenters for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years\u2014United States, 2013[published correction appears in Morb Mortal Wkly Rep. 2013;62(13):256]. MMWR Surveill Summ.2013;62(suppl 1):2-8. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/su6201a2.htm. Accessed February 7, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_002_w2aab3b7b9b1b6b1ab2b1b2Aa","unstructured":"Summary recommendations: prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) \u2014United States, 2013-14. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/flu\/professionals\/acip\/2013-summary-recommendations.htm. Accessed January 29, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_003_w2aab3b7b9b1b6b1ab2b1b3Aa","unstructured":"Adolescent health: overview. HealthyPeople.gov website. http:\/\/www.healthypeople.gov\/2020\/topicsobjectives2020\/overview.aspx?topicId=2#Ref_01. Accessed January 29, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_004_w2aab3b7b9b1b6b1ab2b1b4Aa","unstructured":"Adolescent health: objectives. HealthyPeople.gov website. http:\/\/www.healthypeople.gov\/2020\/topicsobjectives2020\/objectiveslist.aspx?topicId=2. Accessed January 29, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_005_w2aab3b7b9b1b6b1ab2b1b5Aa","unstructured":"Immunization and infectious diseases: overview. HealthyPeople.gov website. http:\/\/www.healthypeople.gov\/2020\/topicsobjectives2020\/overview.aspx?topicid=23. Accessed January 29, 2014."},{"issue":"4","key":"2021042020250770289_j_jaoa.2014.043_ref_006_w2aab3b7b9b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1542\/peds.2012-2384","article-title":"Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010","volume":"131","author":"Darden","year":"2013","journal-title":"Pediatrics"},{"key":"2021042020250770289_j_jaoa.2014.043_ref_007_w2aab3b7b9b1b6b1ab2b1b7Aa","unstructured":"Vaccine information statement: meningococcal vaccines. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/mening.html. Updated October14, 2011. Accessed January 29, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_008_w2aab3b7b9b1b6b1ab2b1b8Aa","unstructured":"Signs & symptoms: meningococcal meningitis. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/meningococcal\/about\/symptoms.html. Accessed February 4, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_009_w2aab3b7b9b1b6b1ab2b1b9Aa","unstructured":"AdamsDAGallagherKMJajoskyRADivision of Notifiable Diseases and Healthcare Information, Office of Surveillance, Epidemiology, and Laboratory Services, CDC. Summary of Notifiable Diseases\u2014United States, 2011. Morb Mortal Wkly Rep.2013;60(53);1-117. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6053a1.htm. Accessed February 2, 2014."},{"issue":"34","key":"2021042020250770289_j_jaoa.2014.043_ref_010_w2aab3b7b9b1b6b1ab2b1c10Aa","first-page":"685","article-title":"National and state vaccination coverage among adolescents aged 13-17 years\u2014United States, 2012","volume":"62","year":"2013","journal-title":"Morb Mortal Wkly Rep."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_011_w2aab3b7b9b1b6b1ab2b1c11Aa","unstructured":"Vaccine information statement: Tdap (tetanus, diphtheria, pertussis). Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/tdap.html. Updated May09, 2013. Accessed January 29, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_012_w2aab3b7b9b1b6b1ab2b1c12Aa","unstructured":"Signs & symptoms: pertussis (whooping cough). Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/pertussis\/about\/signs-symptoms.html. Accessed February 4, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_013_w2aab3b7b9b1b6b1ab2b1c13Aa","unstructured":"June 8, 2006 approval letter\u2014human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant. Food and Drug administration website. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm111283.htm. Accessed February 4, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_014_w2aab3b7b9b1b6b1ab2b1c14Aa","unstructured":"December 22, 2010 approval letter\u2014Gardasil. Food and Drug administration website. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm238074.htm. Accessed February 4, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_015_w2aab3b7b9b1b6b1ab2b1c15Aa","unstructured":"October 16, 2009 approval letter\u2014Cervarix. Food and Drug administration website. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm186959.htm. Accessed February 4, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_016_w2aab3b7b9b1b6b1ab2b1c16Aa","unstructured":"Vaccine information statement: HPV (human papillomavirus) Gardasil. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/hpv-gardasil.html. Updated May17, 2013. Accessed January 29, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_017_w2aab3b7b9b1b6b1ab2b1c17Aa","unstructured":"Vaccine information statement: HPV (human papillomavirus) Cervarix. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/hpv-cervarix.html. Updated May03, 2011. Accessed January 29, 2014."},{"issue":"12","key":"2021042020250770289_j_jaoa.2014.043_ref_018_w2aab3b7b9b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int J Cancer"},{"key":"2021042020250770289_j_jaoa.2014.043_ref_019_w2aab3b7b9b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","first-page":"d5775","DOI":"10.1136\/bmj.d5775","article-title":"Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"},{"key":"2021042020250770289_j_jaoa.2014.043_ref_020_w2aab3b7b9b1b6b1ab2b1c20Aa","unstructured":"American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013:23. http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-036845.pdf. Accessed February 4, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_021_w2aab3b7b9b1b6b1ab2b1c21Aa","unstructured":"Vaccine information statement: inactivated influenza. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/flu.html. Updated July26, 2013. Accessed January 29, 2014."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_022_w2aab3b7b9b1b6b1ab2b1c22Aa","unstructured":"Vaccine information statement: live, intranasal influenza. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/flulive.html. Updated July26, 2013. Accessed January 29, 2014."},{"issue":"1","key":"2021042020250770289_j_jaoa.2014.043_ref_023_w2aab3b7b9b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2004.01382.x","article-title":"Influenza virus: immunity and vaccination strategies: comparison of the immune response to inactivated and live, attenuated influenza vaccines","volume":"59","author":"Cox","year":"2004","journal-title":"Scand J Immunol."},{"key":"2021042020250770289_j_jaoa.2014.043_ref_024_w2aab3b7b9b1b6b1ab2b1c24Aa","unstructured":"March flu vaccination coverage: United States, 2011-12 influenza season. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/flu\/pdf\/fluvaxview\/national-flu-survey-mar2012.pdf. Accessed October 26, 2013."},{"issue":"suppl 1","key":"2021042020250770289_j_jaoa.2014.043_ref_025_w2aab3b7b9b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1542\/peds.2007-1115B","article-title":"New, and some not-so-new, vaccines for adolescents and diseases they prevent","volume":"121","author":"Fishbein","year":"2008","journal-title":"Pediatrics"}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.043\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.043\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T09:59:52Z","timestamp":1619171992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.043\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":25,"journal-issue":{"issue":"s31","published-online":{"date-parts":[[2014,3,1]]},"published-print":{"date-parts":[[2014,3,1]]}},"alternative-id":["10.7556\/jaoa.2014.043"],"URL":"https:\/\/doi.org\/10.7556\/jaoa.2014.043","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,1]]}}}